

Sun Pharmaceutical Industries Ltd.,
SUN HOUSE, CTS No. 201 B/1,
Western Express HI Highway, Goregaon(E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



13 August 2022.

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Update on US FDA Inspection at Mohali Facility

This is to inform you that the US FDA conducted an inspection of Mohali manufacturing facility (Punjab, India) of Sun Pharmaceutical Industries Limited ("the Company") from August 3, 2022 to August 12, 2022. At the conclusion of the inspection, the US FDA issued a Form-483, with 6 observations. The Company is preparing the response to the observations, which will be submitted to US FDA within the stipulated timeline. The Company is committed to address these observations promptly. The Company remains committed to work closely with the US FDA and continues to enhance its compliance on an ongoing basis.

This is for your information and dissemination.

Thanking you,

Yours faithfully,
For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary & Compliance Officer